Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
Ravi K. Amaravadi, MD

Ravi K. Amaravadi, MD Physician

Co-Leader of the Cancer Therapeutics Program, Abramson Cancer Center Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Amaravadi is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2006

Clinical Expertise:

  • Basal Cell Carcinoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Non-Melanoma Skin Cancer
  • Skin Cancer

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania


American Association for Cancer Research, National American Association for the Advancement of Science, National American Society of Clinical Oncology, National Austrian Science Fund (FWF),, International Beyond Batten Disease Foundation, International FWO Belgium Cancer Research, International Health Frontiers Science Program, France, International Health Research Ireland, International Icelandic Research Fund, International Immunaccel Biosciences, National Melanoma Research Foundation Breakthrough Consortium, National Melanoma Research Foundation, National NCI-J special emphasis panel study section for K awards, National Newcastle University, UK, International NIH Loan repayment program, National OPUS, National Science Center, OPUS, International PDX (patient-derived xenografts) Development and Trial Centers Research Network (PDXNet), National Presage Biosciences, National Sprint Biosciences, International The Research Foundation FWO, Belgium, International Welcome Trust DBT alliance Post doctoral fellowships, India, International Wistar Institute, Cancer Center, Tumor Microenvironment and Metastases Program, Local

Hospital Affiliation

Dr. Amaravadi is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Selected Publications:

Parekh Vishwas, Sobanko Joseph, Miller Christopher J, Karakousis Giorgos, Xu Wei, Letrero Richard, Elenitsas Rosalie, Xu Xiaowei, Elder David E, Amaravadi Ravi, Schuchter Lynn M, Nathanson Katherine L, Wilson Melissa A, Chu Emily Y: NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of cutaneous pathology 46 (3): 190-194,2019.

Rebecca Vito W, Nicastri Michael C, Fennelly Colin, Chude Cynthia I, Barber-Rotenberg Julie S, Ronghe Amruta, McAfee Quentin, McLaughlin Noel P, Zhang Gao, Goldman Aaron R, Ojha Rani, Piao Shengfu, Noguera-Ortega Estela, Martorella Alessandra, Alicea Gretchen M, Lee Jennifer J, Schuchter Lynn M, Xu Xiaowei, Herlyn Meenhard, Marmorstein Ronen, Gimotty Phyllis A, Speicher David W, Winkler Jeffrey D, Amaravadi Ravi K: PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer discovery 9 (2): 220-229,2019.

Haas Naomi B, Appleman Leonard J, Stein Mark, Redlinger Maryann, Wilks Melissa, Xu Xiaowei, Onorati Angelique, Kalavacharla Anusha, Kim Taehyong, Zhen Chao Jie, Kadri Sabah, Segal Jeremy P, Gimotty Phyllis A, Davis Lisa E, Amaravadi Ravi K: Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research : 2019.

Ojha Rani, Leli Nektaria M, Onorati Angelique, Piao Shengfu, Verginadis Ioannis I, Tameire Feven, Rebecca Vito W, Chude Cynthia I, Murugan Sengottuvelan, Fennelly Colin, Noguera-Ortega Estela, Liu Shujing, Xu Xiaowei, Krepler Clemens, Xiao Min, Xu Wei, Wei Zhi, Frederick Dennie T, Boland Genevieve, Mitchell Tara C, Karakousis Giorgos C, Schuchter Lynn M, Flaherty Keith T, Zhang Gao, Herlyn Meenhard, Koumenis Constantinos, Amaravadi Ravi K: ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer discovery : 2018.

Baquero Pablo, Dawson Amy, Mukhopadhyay Arunima, Kuntz Elodie M, Mitchell Rebecca, Olivares Orianne, Ianniciello Angela, Scott Mary T, Dunn Karen, Nicastri Michael C, Winkler Jeffrey D, Michie Alison M, Ryan Kevin M, Halsey Christina, Gottlieb Eyal, Keaney Erin P, Murphy Leon O, Amaravadi Ravi K, Holyoake Tessa L, Helgason G Vignir: Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia : 2018.

Kugel Curtis H, Douglass Stephen M, Webster Marie R, Kaur Amanpreet, Liu Qin, Yin Xiangfan, Weiss Sarah A, Darvishian Farbod, Al-Rohil Rami N, Ndoye Abibatou, Behera Reeti, Alicea Gretchen M, Ecker Brett L, Fane Mitchell, Allegrezza Michael J, Svoronos Nikolaos, Kumar Vinit, Wang Daniel Y, Somasundaram Rajasekharan, Hu-Lieskovan Siwen, Ozgun Alpaslan, Herlyn Meenhard, Conejo-Garcia Jose R, Gabrilovich Dmitry, Stone Erica L, Nowicki Theodore S, Sosman Jeffrey, Rai Rajat, Carlino Matteo S, Long Georgina V: Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical cancer research : an official journal of the American Association for Cancer Research : 2018.

Echevarría-Vargas Ileabett M, Reyes-Uribe Patricia I, Guterres Adam N, Yin Xiangfan, Kossenkov Andrew V, Liu Qin, Zhang Gao, Krepler Clemens, Cheng Chaoran, Wei Zhi, Somasundaram Rajasekharan, Karakousis Giorgos, Xu Wei, Morrissette Jennifer Jd, Lu Yiling, Mills Gordon B, Sullivan Ryan J, Benchun Miao, Frederick Dennie T, Boland Genevieve, Flaherty Keith T, Weeraratna Ashani T, Herlyn Meenhard, Amaravadi Ravi, Schuchter Lynn M, Burd Christin E, Aplin Andrew E, Xu Xiaowei, Villanueva Jessie: Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO molecular medicine 10 (5): 2018.

Zhang Gao, Wu Lawrence W, Mender Ilgen, Barzily-Rokni Michal, Hammond Marc R, Ope Omotayo, Cheng Chaoran, Vasilopoulos Themistoklis, Randell Sergio, Sadek Norah, Beroard Aurelie, Xiao Min, Tian Tian, Tan Jiufeng, Saeed Umar, Sugarman Eric, Krepler Clemens, Brafford Patricia A, Sproesser Katrin, Murugan Sengottuvelan, Somasundaram Rajasekharan, Garman Bradley, Wubbenhorst Bradley, Woo Jonathan, Yin Xiangfan, Liu Qin, Frederick Dennie T, Miao Benchun, Xu Wei, Karakousis Giorgos C, Xu Xiaowei, Mitchell Tara C: Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research : 2018.

Monteleon Christine L, Agnihotri Tanvir, Dahal Ankit, Liu Mingen, Rebecca Vito W, Beatty Gregory L, Amaravadi Ravi K, Ridky Todd W: Lysosomes Support the Degradation, Signaling, and Mitochondrial Metabolism Necessary for Human Epidermal Differentiation. The Journal of investigative dermatology : 2018.

Yam Clinton, Xu Xiaowei, Davies Michael A, Gimotty Phyllis A, Morrissette Jennifer J D, Tetzlaff Michael T, Wani Khalida M, Liu Shujing, Deng Wanleng, Buckley Meghan, Zhao Jianhua, Amaravadi Ravi K, Haas Naomi B, Kudchadkar Ragini R, Pavlick Anna C, Sosman Jeffrey A, Tawbi Hussein, Walker Luke, Schuchter Lynn M, Karakousis Giorgos C, Gangadhar Tara C: A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (1): 22-32,2018.

Academic Contact Info

Division of Hematology Oncology
8 BRB - Room 852

Philadelphia, PA 19104
Phone: (215) 769-5159
Patient appointments: 800-789-7366 (PENN)

Related Links